BRAF inhibitor drugs, such as dabrafenib and vemurafenib, inhibit BRAF mutants at the ATP binding site, which impedes BRAF signaling in the MAPK pathway, suppressing tumor growth [10–12]. The gene discussed is BRAF; the disease is neoplasm.